Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-5b777bbd6c-sbgtn Total loading time: 0 Render date: 2025-06-18T07:00:17.735Z Has data issue: false hasContentIssue false

29 - Palliative care and symptom management

from Section X - Specialized interventional techniques in cancer care

Published online by Cambridge University Press:  05 September 2016

By
Drew A. Rosielle ,
Melissa Atwood ,
Sean Marks  and
William S. Rilling
Edited by
Jean-Francois H. Geschwind  and
Michael C. Soulen
Drew A. Rosielle
Affiliation:
University of Minnesota Medical Center
Melissa Atwood
Affiliation:
Children's Hospital of Wisconsin, Milwaukee, WI, USA
Sean Marks
Affiliation:
Medical College of Wisconsin
William S. Rilling
Affiliation:
Medical College of Wisconsin
Jean-Francois H. Geschwind
Affiliation:
Yale University School of Medicine, Connecticut
Michael C. Soulen
Affiliation:
Department of Radiology, University of Pennsylvania Hospital, Philadelphia
Get access

Summary

Palliative care and communication with cancer patients

Overview of palliative care

The World Health Organization defines palliative care as an approach that improves the quality of life of patients and their families facing the problems associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial, and spiritual. Palliative care is focused on symptom relief and maximizing function, without necessarily impacting the natural history of the underlying illness. Bereavement support is integral to its mission as it views the patient and his or her loved ones as a unit of care. Palliative care is interdisciplinary, involving not only nurses and physicians, but chaplains, psychologists, social workers, and speech, physical, occupational, and other therapists. While palliative care has historic roots in the terminal care of cancer patients, its scope encompasses a wide variety of patients with non-malignant diseases. These include neurodegenerative disorders; advanced organ disease; and patients in critical care units. Ideally, palliative care is provided to patients with severe illnesses early in the course of their disease, alongside disease-modifying or curative therapy. As an illness progresses, and as disease-modifying or even life-prolonging interventions become less available, a patient's entire care may become palliative-focused. While much of the care of patients with life-threatening illness can be described as palliative, many patients will not require specialist palliative care, and basic competency in palliative care is important for clinicians across a variety of specialties and practice types.

Palliative medicine describes the physician's role in the aforementioned care model. Besides expert symptom assessment and treatment, palliative medicine physicians offer subspecialty expertise in determining prognosis and communication encounters with patients and families involving breaking bad news, establishing goals of medical care, and planning for the future in light of a life-threatening illness. The scope of practice of palliative medicine physicians varies by location and institution. Common settings include inpatient consultative palliative care services, acute inpatient palliative care wards, outpatient palliative care clinics, cancer pain and symptom management clinics, emergency departments, nursing home palliative care services, and hospice settings. Palliative care is increasing by number of programs and prevalence among adult and pediatric hospitals such that many cancer care providers will have access to palliative care specialists if needed.

Type
Chapter
Information
Interventional Oncology
Principles and Practice of Image-Guided Cancer Therapy
 , pp. 294 - 314
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

1. World Health Organization. WHO definition of palliative care. Available at: www.who.int/cancer/palliative/definition/en. Accessed April 1, 2006.
2. Mosenthal, AC, Murphy, PA. Trauma care and palliative care: time to integrate the two? J Am Coll Surg. 2003; 197:509–516.Google Scholar
3. Curtis, JR, Rubenfeld, GD. Improving palliative care for patients in the intensive care unit. J Palliat Med. 2005; 8:840–854.CrossRefGoogle Scholar
4. von Gunten, CF. Secondary and tertiary palliative care in US hospitals. JAMA. 2002; 287:875–888.CrossRefGoogle Scholar
5. Himelstein, BP, Hilden, JM, Boldt, AM, Weissman, DE. Pediatric palliative care. NEJM. 2004; 350:1752–1762.CrossRefGoogle Scholar
6. www.capc.org/capc-growth-analysis-snapshot-2011.pdf. Accessed 18 Sept 2014.
7. Temel, JS, Greer, JA, Muzikansky, A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010; 363(8):733–742 CrossRefGoogle Scholar
8. Casarett, D, Pickard, A, Bailey, FA, et al. Do palliative consultations improve patient outcomes? J Am Geriatr Soc. 2008; 56(4):593–599.CrossRefGoogle Scholar
9. Norton, SA, Hogan, LA, Holloway, RG, et al. Proactive palliative care in the medical intensive care unit: effects on length of stay for selected high-risk patients. Critical Care Medicine. 2007; 35:1530–1535 CrossRefGoogle Scholar
10. Bendaly, EA, Groves, J, Juliar, B, Gramelspacher, GP. Financial impact of palliative care consultation in a public hospital. J Palliat Med 2008; 11(10):1304–1408.Google Scholar
11. Morrison, RS, Penrod, JD, Cassel, JB, et al. Palliative Care Leadership Centers' Outcomes Group. Cost savings associated with US hospital palliative care consultation programs. Arch Intern Med. 2008; 168(16):1783–1790.CrossRefGoogle Scholar
12. Ranganathan, A, Dougherty, M, Waite, D, Casarett, D. Can palliative home care reduce 30-day readmissions? results of a propensity score matched cohort study. J Palliat Med. 2013; 16(10):1290–1293 CrossRefGoogle Scholar
13. Brumley, R, Enguidanos, S, Jamison, P, et al. Increased satisfaction with care and lower costs: results of a randomized trial of in-home palliative care. J Am Geriatr Soc. 2007; 55: 993–1000.CrossRefGoogle Scholar
14. Morrison, RS, Meier, D. Palliative care. NEJM. 2004; 350:2582–2590.CrossRefGoogle Scholar
15. Weeks, JC, Catalano, PJ, Cronin, A, et al. Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012; 367(17):1616–1625.CrossRefGoogle Scholar
16. Schag, CC, Heinrich, RL, Ganz, PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984; 2:187–193.CrossRefGoogle Scholar
17. Vigano, A, Dorgan, M, Jeanette, B, Bruera, E, Suarez-Almazor, ME. Survival prediction interminal cancer patients: a systematic review of the medical literature. Palliat Med. 2000; 14: 363–374.CrossRefGoogle Scholar
18. Daas, N den. Estimating length of survival in end-stage cancer: a review of the literature. J Pain Symptom Manage. 1995; 10:548–555.CrossRefGoogle Scholar
19. Lamont, EB, Christakis, NA. Complexities in prognostication in advancer cancer. “To help them live their lives the way they want to.” JAMA. 2003; 290:98–104.Google Scholar
20. Maltoni, M, Pirovano, M, Scarpi, E, et al. Prediction of survival of patients terminally ill with cancer. Results of an Italian prospective multicentric study. Cancer. 1995; 75:2613–2622.3.0.CO;2-1>CrossRefGoogle Scholar
21. Reuben, DB, Mor, V, Hiris, J. Clinical symptoms and length of survival in patients with terminal cancer. Arch Int Med. 1988; 148:1586–1591.CrossRefGoogle Scholar
22. Janisch, L, Mick, R, Schilsky, RL, et al. Prognostic factors for survival in patients treated in phase I clinical trials. Cancer. 1994; 74:1965–1973.3.0.CO;2-1>CrossRefGoogle Scholar
23. Maltoni, M, Caraceni, A, Brunelli, C, et al. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations – a study for the steering committee of the European Association for Palliative Care. J Clin Oncol. 2005; 23:6240–6248.CrossRefGoogle Scholar
24. Ralson, SH, Gallacher, SJ, Patel, U, Campbell, J, Boyle, IT. Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med. 1990; 112:499–504.CrossRefGoogle Scholar
25. Iwase, M, Kurachi, Y, Kakuta, S, et al. Clin Oral Investig. 2001; 5:194–198.
26. Siddiqui, F, Weissman, DE. Fast facts and concepts #151; Hypercalcemia of malignancy. February 2006. End-of-Life Physician Education Resource Center. www.eperc.mcw.edu.
27. Khuntia, D, Brown, P, Li, J, Mehta, MP. Whole-brian radiotherapy in the management of brain metastasis. J Clin Onc. 2006; 24:1295–1304.CrossRefGoogle Scholar
28. McMillan, DC. The systemic inflammation-based glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013; 39(5):534–540.CrossRefGoogle Scholar
29. Gripp, S, Moeller, S, Bolke, E, et al. Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol. 2007; 25(22):3313–3320.CrossRefGoogle Scholar
30. Christakis, NA, Lamont, EB. Extent and determinants of error in physicians’ prognoses in terminally ill patients: prospective cohort study. West J Med. 2000; 172(5):310–313.CrossRefGoogle Scholar
31. Glare, P, Virik, K, Jones, M, et al. A systematic review of physicians’ survival predictions in terminally ill cancer patients. BMJ. 2003; 327:195–201.CrossRefGoogle Scholar
32. Christakis, NA, Lamont, EB. Extent and determinants of error in doctors’ prognoses in terminally ill patients: prospective cohort study. BMJ. 2000; 320:469–473.CrossRefGoogle Scholar
33. Lamont, EB, Christakis, NA. Prognostic disclosure to patients with cancer near the end of life. Ann Int Med. 2001; 134:1096–1105.CrossRefGoogle Scholar
34. Hagerty, RG, Butow, PN, Ellis, PM, Dimitry, S, Tattersall, MH. Communicating prognosis in cancer care: a systematic review of the literature. Ann Oncol. 2005; 16:1005–1053.CrossRefGoogle Scholar
35. Randall, TC, Wearn, AM. Receiving bad news: patients with haematological cancer reflect upon their experience. Palliat Med. 2005; 19:594–601.CrossRefGoogle Scholar
36. Weissman, DE. Fast facts and concepts #13; Determining prognosis in advanced cancer. 2nd Edition, July 2005. End-of-Life Palliative Education Resource Center. www.eperc.mcw.edu.
37. Ambuel, B, Weissman, DE. Fast facts and concepts #6; Delivering bad news: part 1. 2nd Edition, July 2005. End-of-Life Palliative Education Resource Center. www.eperc.mcw.edu.
38. Ambuel, B, Weissman, DE. Fast facts and concepts #11; Delivering bad news; part 2. 2nd Edition, September 2005. End-of-Life Palliative Education Resource Center. www.eperc.mcw.edu.
39. Weissman, DE. Decision making at a time of crisis near the end of life. JAMA. 2004; 292:1738–1743.CrossRefGoogle Scholar
40. Lussier, D, Huskey, AF, Portenoy, RK. Adjuvant analgesics in cancer pain management. The Oncol. 2004; 9:571–591.CrossRefGoogle Scholar
41. Mercadante, S, Portenoy, RK. Opioid poorly-responsive cancer pain. Part 1: clinical considerations. J Pain Symptom Manage. 2001; 21:144–150.Google Scholar
42. Thomas, JR, Gunten, CF von. Pain in terminally ill patients. Guidelines for pharmacological management. CNS Drugs. 2003; 17:621–631.Google Scholar
43. Cherny, NI. Cancer pain: principles of assessment and syndromes. In: Berger, AM, Portenoy, RK, Weissman, DE, eds. Principles and Practice of Palliative Care and Supportive Oncology, 2nd edition. New York, NY: Lippincott Williams and Wilkins; 2002:3–52.
44. Menefee, LA, Monti, DA. Nonpharmacologic and complementary approaches to cancer pain management. J Am Osteopath Assoc. 2005; 105:S15–20.Google Scholar
45. Hillard, RE. Music therapy in hospice and palliative care: a review of the empirical data. eCAM. 2005; 2:173–178.Google Scholar
46. Mercadante, S, Casuccio, A, Agnello, A, Pumo, S, et al. Analgesic effects of nonsteroidal anti-inflammatory drugs in cancer pain due to somatic or visceral mechanisms. J Pain Symptom Manage. 1999; 17:351–356.CrossRefGoogle Scholar
47. Mercadante, S, Fulfaro, F, Casuccio, A. A randomized controlled study on the use of anti-inflammatory drugs in patients with cancer pain on morphine therapy: effects on dose-escalation and a pharmacoeconomic analysis. Eu J Cancer. 2002; 38:1358–1363.CrossRefGoogle Scholar
48. Davis, MP, Walsh, D, Lagman, R, LeGrand, SB. Controversies in pharmacotherapy of pain management. Lancet Oncol. 2005; 6:696–704.CrossRefGoogle Scholar
49. Leppert, W, Luczak, J. The role of tramadol in cancer pain treatment – a review. Supp Care Cancer. 2005; 13:5–17 CrossRefGoogle Scholar
50. Hanks, GW, Conno, F de, Cherny, N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001; 84:587–593 CrossRefGoogle Scholar
51. Gutstein, HB, Akil, H. Opioid analgesics. In: Hardman, JG, Limbird, LE, eds. Goodman and Gilman's: the Pharmacological Basis of Therapeutics, 10th Ed. New York, NY: McGraw-Hill; 2001:569–619.
52. Weissman, DE. Fast facts and concepts #71: Meperidine for pain: What's all the fuss? June 2002. End-of-Life Physician Education Resource Center. www.eperc.mcw.edu.
53. Aranoff, GM, Brennan, MJ, Douglas, PD, Ginsberg, B. Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines. Pain Med. 2005; 6: 305–314.CrossRefGoogle Scholar
54. Bruera, E, Sweeney, C. Methadone use in cancer patients with pain: a review. J Palliative Med. 2002; 5:127–138.CrossRefGoogle Scholar
55. Gordon DB, Weissman DE. Fast facts and concepts #70: PRN range analgesic orders. June 2002. End-of-Life Physician Education Resource Center. www.eperc.mcw.edu.
56. Quigley, C. The role of opioids in cancer pain. BMJ. 2005; 331:825–829.CrossRefGoogle Scholar
57. Dean, M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004; 28:497–504.CrossRefGoogle Scholar
58. Paice, JA, Toy, C, Shott, S. Barriers to cancer pain relief: fear of tolerance and addiction. J Pain Symptom Manage. 1998; 16:1–9.CrossRefGoogle Scholar
59. Sloan, P, Melzack, R. Long-term patterns of morphine dose and pain intensity among cancer patients. Hosp J. 1999; 14:35–47.CrossRefGoogle Scholar
60. Collin, E, Poulain, P, Gauvain-Piquard, A, et al. Is disease progression the major factor in morphine ‘tolerance’ in cancer pain treatment? Pain. 1993; 55:319–326.Google Scholar
61. National Cancer Institute. Substance Abuse Issues In Cancer (PDQ). Available at: www.cancer.gov/cancertopics/pdq/supportivecare/substanceabuse/healthprofessional. Accessed April 1, 2006.
62. Passik, SD, Kirsh, KL, Caspar, D. Addiction-related assessment tools and pain management: instruments for screening, treatment planning, and monitoring compliance. Pain Med 2008; 9:S145–166 Google Scholar
63. Chou, R, Fanciullo, GJ, Fine, PG, Miaskowski, C, Passik, SD, Portenoy, RK. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine Clinical Practice Guideline. J Pain. 2009; 10(2):131–146 CrossRefGoogle Scholar
64. Claxton, R, Arnold, R. Screening for opioid misuse and abuse. Fast Facts and Concepts. August 2011; 244. www.eperc.mcw.edu/EPERC/FastFactsIndex/ff_244.htm Google Scholar
65. [Anonymous]. Management of chronic pain syndromes: issues and interventions. Pain Med. 2005; 6: S1–S21.
66. Caraceni, A, Zecca, E, Bonezzi, C, et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the gabapentin cancer pain study group. J Clin Oncol. 2004; 22:2909–2917.CrossRefGoogle Scholar
67. McDonald, AA, Portenoy, RK. How to use antidepressants and anticonvulsants as adjuvant analgesics in the treatment of neuropathic cancer pain. J Supp Oncol. 2006; 4:43–52.Google Scholar
68. Smith, EM, Pang, H, Cirrincione, C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013; 309(13):1359–1367.CrossRefGoogle Scholar
69. Hanks, GW. The pharmacological treatment of bone pain. Cancer Surv. 1988; 7:87–101.Google Scholar
70. Hamouda, WE, Roshdy, W, Teema, M. Single versus conventional fractionated radiotherapy in the palliation of painful bone metastases. Gulf J Oncolog. 2007; 1(1):35–41.Google Scholar
71. Hayashi, S, Tanaka, H, Hoshi, H. External beam radiotherapy for painful bone metastases from hepatocellular carcinoma: multiple fractions compared with an 8-gy single fraction. Nagoya J Med Sci. 2014; 76(1–2):91–99.Google Scholar
72. Wu, JS, Wong, R, Johnston, M, Bezjak, A, Whelan, T, Cancer Care Ontario Practice Guidelines Initiative Supportive Care Group. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys. 2003; 55(3):594–605.CrossRefGoogle Scholar
73. Callstrom, MR, Charboneau, JW. Percutaneous ablation: safe, effective treatment of bone tumors. Oncology (Williston Park). 2005; 19(11 Suppl 4):22–26.Google Scholar
74. Posteraro, AF, Dupuy, DE, Mayo-Smith, WW. Radiofrequency ablation of bony metastatic disease. Clin Radiol. 2004; 59(9):803–811.CrossRefGoogle Scholar
75. Finlay, IG, Mason, MD, Shelley, M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005; 6:392–400.CrossRefGoogle Scholar
76. Posteraro, AF, Dupuy, DE, Mayo-Smith, WW. Radiofrequency ablation of bony metastatic disease. Clin Radiol. 2004; 59:803–811.CrossRefGoogle Scholar
77. Hacein-Bey, L, Baisden, JL, Lemke, DM, et al. Treating osteoporotic and neoplastic vertebral compression fractures with vertebroplasty and kyphoplasty. J Palliat Med. 2005; 8:931–938.CrossRefGoogle Scholar
78. Elkersh, MA, Simopoulos, TT, Bajwa, ZH. Fundamentals of interventional pain medicine. The Neurol. 2005; 11:285–293.Google Scholar
79. Wong, GY, Schroeder, DR, Carns, PE. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer. A randomized controlled trial. JAMA. 2004; 291:1092–1099.CrossRefGoogle Scholar
80. Davis, MP, Walsh, D. Treatment of nausea and vomiting in advanced cancer. Support Care Cancer. 2000; 8:444–452.CrossRefGoogle Scholar
81. Boer-Dennert, M de, Wit, R de, Schmitz, PI, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer. 1997; 76:1055–61.CrossRefGoogle Scholar
82. Aapro, M. 5-HT3-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment. Oncology. 2005; 69:97–109.CrossRefGoogle Scholar
83. Olver, IN. Update on anti-emetics for chemotherapy-induced emesis. Intern Med J. 2005; 35:478–481.CrossRefGoogle Scholar
84. Hesketh, PJ, Grunberg, SM, Gralla, RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003; 21:4077–4080.Google Scholar
85. Herrstedt, J, Muss, HB, Warr, DG, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer. 2005; 104:1548–1555.CrossRefGoogle Scholar
86. Hocking, CM, Kichenadasse, G. Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer. 2014; 22(4):1143–1151 CrossRefGoogle Scholar
87. Chung, F, Lane, R, Spraggs, C, et al. Ondansetron is more effective than metoclopramide for the tratement of opioid-induced emesis in post-surgical adult patients. Ondansetron OIE Post-Surgical Study Group. Eur J Anaesthesiol. 1999; 16:669–677.Google Scholar
88. Glare, P, Pereira, G, Kristjanson, LJ, Stocker, M, Tattersall, M. Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer. Supp Care Cancer. 2004; 12:432–440.CrossRefGoogle Scholar
89. Bruera, E, Seifert, L, Watanabe, S, et al. Chronic nausea in advancer cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. J Pain Symptom Manage. 1996; 11:147–153.CrossRefGoogle Scholar
90. Mystakidou, K, Befon, S, Liossi, C, Vlachos, L. Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer. Cancer. 1998; 83:1214–1243.3.0.CO;2-7>CrossRefGoogle Scholar
91. Critchley, P, Plach, N, Grantham, M, et al. Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative patient: a systematic review. J Pain Symptom Manage. 2001; 22:631–634.CrossRefGoogle Scholar
92. Passik, SD, Lundbert, J, Kirsh, KL. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage. 2002; 23:526–532.CrossRefGoogle Scholar
93. Passik, SD, Kirsh, KL, Theobald, DE, et al. A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage. 2003; 25:485–488.CrossRefGoogle Scholar
94. Navari, RM, Einhorn, LH, Passik, SD, et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Supp Care Cancer. 2005; 13:529–534.CrossRefGoogle Scholar
95. Mizukami, N, Yamauchi, M, Koike, K, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J Pain Symptom Manage. 2014; 47(3):542–550.CrossRefGoogle Scholar
96. Basch, E, Prestrud, AA, Hesketh, PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011; 29(31):4189–4198.CrossRefGoogle Scholar
97. Navari, RM, Nagy, CK, Gray, SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supp Care Cancer. 2013; 21(6):1655–1663.CrossRefGoogle Scholar
98. Tramer, MR, Carroll, D, Campbell, FA, Reynolds, DJ, Moore, RA, McQuay, HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001; 323:1–8.Google Scholar
99. Walsh, D, Nelson, KA, Mahmoud, FA. Established and potential therapeutic applications of cannabinoids in oncology. Supp Care Cancer. 2003; 11:137–143.Google Scholar
100. www.ncsl.org/research/health/state-medical-marijuana-laws.aspx. Accessed June 23, 2014.
101. Swift, W, Gates, P, Dillon, P. Survey of Australians using cannabis for medical purposes. Harm Reduct J. 2005; 2:18.CrossRefGoogle Scholar
102. Walsh, Z, Callaway, R, Belle-Isle, L, et al. Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. Int J Drug Policy. 2013; 24(6):511–516.CrossRefGoogle Scholar
103. Bowles, DW, O'Bryant, CL, Camidge, DR, Jimeno, A. The intersection between cannabis and cancer in the United States. Crit Rev Oncol Hematol. 2012; 83(1):1–10.CrossRefGoogle Scholar
104. Malik, IA, Khan, WA, Qazilbash, M, Ata, E, Butt, A, Khan, MA. Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol. 1995; 18:170–175.CrossRefGoogle Scholar
105. Ezzo, J, Vickers, A, Richardson, MA, et al. Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting. J Clin Onc. 2005; 23:7188–7198.CrossRefGoogle Scholar
106. Roscoe, JA, Morrow, GR, Hickok, JT, et al. The efficacy of acupressure and acustimulation wrist bands for the relief of chemotherapy-induced nausea and vomiting. A University of Rochester Cancer Center Community Clinical Oncology Program multicenter study. J Pain Symptom Manage. 2003; 26:731–742.Google Scholar
107. , I, Bruera, E. Constipation in advanced cancer patients. Supp Care Cancer. 1998; 6:356–364.CrossRefGoogle Scholar
108. Homsi, J, Walsh, D, Rivera, N, et al. Symptom evaluation in palliative medicine: patients report vs systematic assessment. Supp Care Cancer. 2006; 14:444–453.CrossRefGoogle Scholar
109. Fallon, M, O'Neill, B. ABC of palliative care: constipation and diarrhoea. BMJ. 1997; 315:1293–1296.CrossRefGoogle Scholar
110. Tamayo, AC, Diaz-Zuluaga, PA. Management of opioid-induced bowel dysfunction in cancer patients. Supp Care Cancer. 2004; 12:613–618.Google Scholar
111. Allan, L, Richarz, U, Simpson, K, Slappendel, R. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain. Spine. 2005; 30:2484–2490.CrossRefGoogle Scholar
112. Meissner, W, Schmidt, U, Hartmann, M, Kath, R, Reinhart, K. Oral naloxone reverses opioid-associated constipation. Pain. 2000; 84:105–109.CrossRefGoogle Scholar
113. Sykes, NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med. 1996; 10:135–44.CrossRefGoogle Scholar
114. Clemens, KE, Faust, M, Jaspers, B, Mikus, G. Pharmacological treatment of constipation in palliative care. Curr Opin Support Palliat Care. 2013; 7(2):183–191.CrossRefGoogle Scholar
115. Thomas, J, Karver, S, Cooney, GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008; 358(22):2332–2343.CrossRefGoogle Scholar
116. Portenoy, RK, Thomas, J, Boatwright, ML Moehl, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage. 2008; 35(5):458–468.CrossRefGoogle Scholar
117. Yavuzsen, T, Davis, MP, Walsh, D, LeGrand, S, Lagman, R. Systematic review of the treatment of cancer–associated anorexia and weight loss. J Clin Oncol. 2005; 23:8500–8511.CrossRefGoogle Scholar
118. Body, JJ. The syndrome of anorexia–cachexia. Curr Opin Oncol. 1999; 11:225–260.Google Scholar
119. MacDonald, N. Is there evidence for earlier intervention in cancer-associated weight loss? J Supp Oncol. 2003; 1:279–286.Google Scholar
120. Wilcock, A. Anorexia: a taste of things to come? Palliat Med. 2006; 20:43–45.Google Scholar
121. Simons, JP, Schols, AM, Hoefnagels, JM, Westerterp, KR, Velde, GP ten, Wouters, EF. Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial. Cancer. 1998; 82:553–560.3.0.CO;2-0>CrossRefGoogle Scholar
122. Desport, JC, Gory-Delabaere, G, Blanc-Vincent, MP, et al. Standards, options, and recommendations for the use of appetite stimulants in oncology (2000). Br J Cancer. 2003; 89:S98–S100.Google Scholar
123. Sood, A, Moynihan, TJ. Cancer-related fatigue: an update. Curr Oncol Rep. 2005; 7:277–282.CrossRefGoogle Scholar
124. Raison, CL, Miller, AH. Depression in cancer: new developments regarding diagnosis and treatment. Biol Psychiat. 2003; 54:283–294.CrossRefGoogle Scholar
125. Hickok, JT, Roscoe, JA, Morrow, GR, Mustian, K, Okunieff, P, Bole, CW. Frequency, severity, clinical course, and correlates of fatigue in 372 patients during 5 weeks of radiotherapy for cancer. Cancer. 2005; 104:1772–1778.CrossRefGoogle Scholar
126. Ahlberg, K, Ekman, T, Gaston-Johansson, F, Mock, V. Assessment and management of cancer-related fatigue in adults. Lancet. 2003; 362:640–650.CrossRefGoogle Scholar
127. Adamsen, L. Midtgaard, J, Andersen, C, Quist, M, Moeller, T, Roerth, M. Transforming the nature of fatigue through exercise: qualitative findings from a multidimensional exercise programme in cancer patients undergoing chemotherapy. Eur J Cancer Care. 2004; 13:362–370.CrossRefGoogle Scholar
128. Patrick, D, Gagnon, DD, Zagari, MJ, et al. Assessing the clinical significance of health-related quality of life (HRQoL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 2003; 39:335–345.Google Scholar
129. Mock, V. Evidence-based treatment for cancer-related fatigue. J Natl Cancer Inst Monograph. 2004; 32:112–118.Google Scholar
130. Smith, RE. Erythropoietic agents in the management of cancer patients. Part 1: Anemia, quality of life, and possible effects on survival. J Supp Oncol. 2003; 1:249–258.Google Scholar
131. Munch, TN, Zhang, T, Wiley, J, Palmer, JL, Bruera, E. The association between anemia and fatigue in patients with advanced cancer receiving palliative care. J Palliat Med. 2005; 8:1144–1149.CrossRefGoogle Scholar
132. Monti, M, Castellani, L, Berlusconi, A, Cunietti, E. Use of red blood cell transfusions in terminally ill cancer patients admitted to a palliative care unit. J Pain Symptom Manage. 1996; 12:18–22.CrossRefGoogle Scholar
133. Bruera, E, Driver, L, Barnes, EA. Patient-controlled methylphenidate for the management of fatigue in patients with advancer cancer: a preliminary report. J Clin Oncol. 2003; 21:4439–4443.CrossRefGoogle Scholar
134. Schwartz, AL, Mori, M, Gao, R, Nail, LM, King, ME. Exercise reduces daily fatigue in women with breast cancer receiving chemotherapy. Med Sci Sports Exerc. 2001; 33:718–723.CrossRefGoogle Scholar
135. Dimeo, FC, Stieglitz, RD, Novelli-Fischer, U, Fetscher, S, Keul, J. Effects of physicial activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer. 1999; 85:2273–2277.3.0.CO;2-B>CrossRefGoogle Scholar
136. Iop, A, Manfredi, AM, Bonura, S. Fatigue in cancer patients receiving chemotherapy: an analysis of published studies. Ann Oncol. 2004; 15:712–720.CrossRefGoogle Scholar
137. Covey, AM. Management of malignant pleural effusions and ascites. J Supp Oncol. 2005; 3:169–176.Google Scholar
138. Garrison, RN, Kaelin, LD, Galloway, RH, Heuser, LS. Malignant ascites. Clinical and experimental observations. Ann Surg. 1986; 203:644–651.CrossRefGoogle Scholar
139. Runyon, BA, Hoefs, JC, Morgan, TR. Ascitic fluid analysis in malignancy-related ascites. Hepatol. 1988; 8:1104–1109.CrossRefGoogle Scholar
140. Lee, CW, Bociek, G, Faught, W. A survey of practice in management of malignant ascites. J Pain Symptom Manage. 1998; 16:96–101.CrossRefGoogle Scholar
141. Marrero, J, Martinez, FJ, Hyzy, R. Advances in critical care hepatology. Am J Respir Crit Care Med. 2003; 168:1421–1426.CrossRefGoogle Scholar
142. Aass, N, Fossa, SD, Dahl, AA, Moe, TJ. Prevalence of anxiety and depression in cancer patients seen at the Norwegian Radium Hospital. Eur J Cancer. 1997; 33:1597–604.CrossRefGoogle Scholar
143. Pirl, WF. Evidence report on the occurrence, assessment, and treatment of depression in cancer patients. J Natl Cancer Inst Monograph. 2004; 32:32–39.Google Scholar
144. Stiefel, F, Trill, MD, Berney, A, Olarte, JM, Razavi, D. Depression in palliative care: a pragmatic report from the Expert Working Group of the European Association for Palliative Care. Supp Care Cancer. 2001; 9:477–488.CrossRefGoogle Scholar
145. Ebmeier, KP, Donaghey, C, Steel, JD. Recent developments and current controversies in depression. Lancet. 2006; 367:153–167.CrossRefGoogle Scholar
146. Goodwin, JS, Zhang, DD, Ostir, GV. Effect of depression on diagnosis, treatment, and survival of older women with breast cancer. J Am Geri Soc. 2004; 52:106–111.CrossRefGoogle Scholar
147. Hjerl, K, Andersen, EW, Keiding, N, Mouridsen, HT, Mortensen, PB, Jorgensen, T. Depression as a prognostic factor for breast cancer mortality. Psychosomat. 2003; 44:24–30.CrossRefGoogle Scholar
148. Passik, SD, Dugan, W, McDonald, MV, Rosenfeld, B, Theobald, DE, Edgerton, S. Oncologists’ recognition of depression in their patients with cancer. J Clin Oncol. 1998; 16:1594–1600.CrossRefGoogle Scholar
149. Periyakoil, VJ. Fast facts and concepts #43: Is it grief or depression? August 2005. 2nd edition. End-of-Life Physician Education Resource Center. www.eperc.mcw.edu
150. Chochinov, HM, Wilson, KG, Enns, M, Lander, S. “Are you depressed?” Screening for depression in the terminally ill. Am J Psychiat. 1997; 154:674–676.CrossRefGoogle Scholar
151. Arnold, RA. Fast fact and concept #146: Screening for depression in palliative care. December 2005. End-of-Life Physician Education Resource Center. www.eperc.mcw.edu.
152. Holland, JC, Morrow, GR, Schmale, A, et al. A randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms. J Clin Oncol. 1991; 9:1004–1011.CrossRefGoogle Scholar
153. Sheard, T, Maguire, P. The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses. Br J Cancer. 1999; 80:1770–1780.CrossRefGoogle Scholar
154. Thase, ME, Greenhouse, JB, Frank, E, et al. Treatment of major depression with psychotherapy or psychotherapy–pharmacotherapy combinations. Arch Gen Psychiatry. 1997; 54:1009–15.CrossRefGoogle Scholar
155. Temel, JS, Greer, JA, Muzikansky, A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010; 363(8):733–742.CrossRefGoogle Scholar
156. Clark, DB, Andrus, MR, Byrd, DC. Drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literature. Pharmacother. 2006; 25:269–276.Google Scholar
157. Weinrieb, RM, Auriacombe, M, Lynch, KG, Lewis, JD. Selective serotonin re-uptake inhibitors and the risk of bleeding. Expert Opin Drug Safety. 2005; 4:337–344.CrossRefGoogle Scholar
158. Kroenke, K, Messina, N, Benattia, I, Graepel, J, Musgnung, J. Vanlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder. J Clin Psychiat. 2006; 67:72–80.CrossRefGoogle Scholar
159. Raskin, J, Pritchett, YL, Wang, F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005; 6:346–356.CrossRefGoogle Scholar
160. Theobald, DE, Kirsh, KL, Holtsclaw, E, Donaghy, K, Passik, SD. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage. 2002; 23:442–447.CrossRefGoogle Scholar
161. Pereira, J, Bruera, E. Depression with psychomotor retardation: diagnostic challenges and the use of psychostimulants. J Palliat Med. 2001; 4:15–21.CrossRefGoogle Scholar
162. Burgess, C, Cornelius, V, Love, S, Graham, J, Richards, M, Ramierez, A. Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ. 2005; 330:702.CrossRefGoogle Scholar
163. Hipkins, J, Whitworth, M, Tarrier, N, Jayson, G. Social support, anxiety and depression after chemotherapy for ovarian cancer: a prospective study. Br J Health Psychol. 2004; 9:569–581.CrossRefGoogle Scholar
164. Fowler, JM, Carpenter, KM, Gupta, P, Golden-Kreutz, DM, Andersen, BL. The gynecologic oncology consult: symptom presentation and concurrent symptoms of depression and anxiety. Obstet Gynecol. 2004; 103:1211–1217.CrossRefGoogle Scholar
165. Fellowes, D, Barnes, K, Wilkinson, S. Aromatherapy and massage for symptom relief in patients with cancer. Cochrane Database of Systematic Reviews. (2): CD002287, 2004.Google Scholar
166. Sloman, R. Relaxation and imagery for anxiety and depression control in community patients with advanced cancer. Cancer Nurs. 2002; 25:432–435.CrossRefGoogle Scholar
167. Bottomley, A. Anxiety and the adult cancer patient. Eur J Cancer Care. 1998; 7:217–224.Google Scholar
168. Goodman, WK. Selecting pharmacotherapy for generalized anxiety disorder. J Clin Psychiat. 2004; 65:S8–S13.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×